Search PubMed⌕ Search

Biomedical subjects

Mark J Tullman

Publications and source records attributed to Mark J Tullman.

4 recordsLinked to original sources
PubMed2005

Combination therapy in multiple sclerosis.

Over the past decade, multiple sclerosis (MS) has become a treatable neurologic illness. However, given the rather modest benefit of the currently available disease-modifying agents, as well as the challenges associated with performing placebo-controlled, equivalence, and superiority trials, the logic of combining therapies in MS has considerable appeal. Selecting agents for combination requires careful consideration, as the immunomodulating activity of one drug could potentially interfere with the therapeutic effect of another, and certain combinations may be associated with unforeseen adverse effects. Rigorously controlled studies are needed to determine the safest and most effective use of new and existing MS therapies.

Clinical Trials as Topic↗
PubMed2003

Magnetic resonance imaging of meningoradiculomyelitis in early disseminated Lyme disease.

Lyme disease, a multisystem illness caused by the spirochete Borrelia burgdorferi, is the most common vector-borne disease in the United States. There are 3 clinical stages of Lyme disease: early localized, early disseminated, and late persistent disease. Neuroborreliosis, infection of the nervous system by B. burgdorferi, may occur during early disseminated or late persistent disease. Spinal cord involvement in early disseminated disease is extremely rare. In patients with early disseminated neuroborreliosis, treatment with antibiotics often leads to rapid recovery and may prevent further complications of Lyme disease. The authors present the clinical and radiographic findings, both before and after treatment, in a patient with meningoradiculomyelitis due to early disseminated Lyme disease.

Adult↗
PubMedDate not supplied

Immunotherapy of multiple sclerosis--current practice and future directions.

Over the past decade, multiple sclerosis (MS) has become a treatable neurological disease. This paper reviews the therapies that have been studied to treat MS and discusses various treatment approaches on the horizon. Immunosuppressive and immunomodulatory therapies have been shown to alter the long-term course of MS. Therapies are currently available for relapsing-remitting, secondary progressive, and progressive relapsing disease. Although effective, these therapies have a modest impact on reduction in relapse rate and slowing of disease progression. Much work is needed to improve upon this modest effect and hopefully obtain a cure.

Adjuvants, Immunologic↗